de Morgan Stanley BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 20 M | Vender |
1,999,684
-23,304
| -1% | -USD 211 k | ﹤0.01% | 3100 |
|
|
2026
Q1 | USD 19.3 M | Comprar |
2,022,988
+277,425
| +16% | +USD 2.15 M | ﹤0.01% | 2999 |
|
|
2025
Q4 | USD 13.6 M | Vender |
1,745,563
-3,457,396
| -66% | -USD 25 M | ﹤0.01% | 3315 |
|
|
2025
Q3 | USD 39.5 M | Vender |
5,202,959
-126,720
| -2% | -USD 1.06 M | ﹤0.01% | 2219 |
|
|
2025
Q2 | USD 47.8 M | Comprar |
5,329,679
+3,032,005
| +132% | +USD 28.2 M | ﹤0.01% | 1976 |
|
|
2025
Q1 | USD 17.2 M | Comprar |
2,297,674
+631,942
| +38% | +USD 5.1 M | ﹤0.01% | 2847 |
|
|
2024
Q4 | USD 12.5 M | Vender |
1,665,732
-73,348
| -4% | -USD 557 k | ﹤0.01% | 3212 |
|
|
2024
Q3 | USD 13.2 M | Comprar |
1,739,080
+161,131
| +10% | +USD 1.22 M | ﹤0.01% | 3208 |
|
|
2024
Q2 | USD 9.8 M | Vender |
1,577,949
-430,096
| -21% | -USD 2.37 M | ﹤0.01% | 3346 |
|
|
2024
Q1 | USD 10.2 M | Vender |
2,008,045
-1,128,643
| -36% | -USD 6.35 M | ﹤0.01% | 3334 |
|
|
2023
Q4 | USD 18.8 M | Comprar |
3,136,688
+1,310,864
| +72% | +USD 7.6 M | ﹤0.01% | 2749 |
|
|
2023
Q3 | USD 12.9 M | Comprar |
1,825,824
+956,027
| +110% | +USD 6.87 M | ﹤0.01% | 2881 |
|
|
2023
Q2 | USD 6.12 M | Vender |
869,797
-740,873
| -46% | -USD 5.95 M | ﹤0.01% | 3610 |
|
|
2023
Q1 | USD 13.4 M | Comprar |
1,610,670
+454,939
| +39% | +USD 4.38 M | ﹤0.01% | 2864 |
|
|
2022
Q4 | USD 13.3 M | Comprar |
1,155,731
+246,462
| +27% | +USD 3.07 M | ﹤0.01% | 2778 |
|
|
2022
Q3 | USD 11.5 M | Vender |
909,269
-3,466,300
| -79% | -USD 44.6 M | ﹤0.01% | 2802 |
|
|
2022
Q2 | USD 46.3 M | Comprar |
4,375,569
+3,665,522
| +516% | +USD 37.8 M | 0.01% | 1427 |
|
|
2022
Q1 | USD 11.5 M | Comprar |
710,047
+333,678
| +89% | +USD 5.35 M | ﹤0.01% | 2749 |
|
|
2021
Q4 | USD 5.21 M | Vender |
376,369
-49,008
| -12% | -USD 649 k | ﹤0.01% | 3677 |
|
|
2021
Q3 | USD 6.11 M | Vender |
425,377
-486,828
| -53% | -USD 7.68 M | ﹤0.01% | 3463 |
|
|
2021
Q2 | USD 14.4 M | Comprar |
912,205
+654,998
| +255% | +USD 8.9 M | ﹤0.01% | 2549 |
|
|
2021
Q1 | USD 2.62 M | Vender |
257,207
-17,940
| -7% | -USD 185 k | ﹤0.01% | 4048 |
|
|
2020
Q4 | USD 2.05 M | Comprar |
275,147
+81,750
| +42% | +USD 421 k | ﹤0.01% | 4137 |
|
|
2020
Q3 | USD 664 k | Vender |
193,397
-18,996
| -9% | -USD 81.4 k | ﹤0.01% | 4481 |
|
|
2020
Q2 | USD 1.01 M | Vender |
212,393
-479,755
| -69% | -USD 1.92 M | ﹤0.01% | 4157 |
|
|
2020
Q1 | USD 1.38 M | Comprar |
692,148
+183,081
| +36% | +USD 504 k | ﹤0.01% | 3685 |
|
|
2019
Q4 | USD 1.76 M | Vender |
509,067
-739,249
| -59% | -USD 1.86 M | ﹤0.01% | 4134 |
|
|
2019
Q3 | USD 3.58 M | Vender |
1,248,316
-164,337
| -12% | -USD 511 k | ﹤0.01% | 3247 |
|
|
2019
Q2 | USD 5.35 M | Comprar |
1,412,653
+1,045,869
| +285% | +USD 6.29 M | ﹤0.01% | 2856 |
|
|
2019
Q1 | USD 2.99 M | Comprar |
366,784
+183,081
| +100% | +USD 1.57 M | ﹤0.01% | 3223 |
|
|
2018
Q4 | USD 1.48 M | Vender |
183,703
-9,016
| -5% | -USD 70.1 k | ﹤0.01% | 4005 |
|
|
2018
Q3 | USD 1.47 M | Vender |
192,719
-48,610
| -20% | -USD 326 k | ﹤0.01% | 4236 |
|
|
2018
Q2 | USD 1.38 M | Vender |
241,329
-200,102
| -45% | -USD 1.1 M | ﹤0.01% | 4393 |
|
|
2018
Q1 | USD 2.11 M | Comprar |
441,431
+52,726
| +14% | +USD 271 k | ﹤0.01% | 3967 |
|
|
2017
Q4 | USD 1.91 M | Comprar |
388,705
+26,565
| +7% | +USD 129 k | ﹤0.01% | 4071 |
|
|
2017
Q3 | USD 1.9 M | Comprar |
362,140
+44,241
| +14% | +USD 227 k | ﹤0.01% | 3937 |
|
|
2017
Q2 | USD 1.77 M | Vender |
317,899
-156,286
| -33% | -USD 952 k | ﹤0.01% | 3910 |
|
|
2017
Q1 | USD 3.98 M | Comprar |
474,185
+146,220
| +45% | +USD 1.02 M | ﹤0.01% | 3106 |
|
|
2016
Q4 | USD 2.08 M | Comprar |
327,965
+302,642
| +1,195% | +USD 1.57 M | ﹤0.01% | 3893 |
|
|
2016
Q3 | USD 112 k | Comprar |
25,323
+8,529
| +51% | +USD 34.1 k | ﹤0.01% | 5259 |
|
|
2016
Q2 | USD 48 k | Vender |
16,794
-163,431
| -91% | -USD 507 k | ﹤0.01% | 5547 |
|
|
2016
Q1 | USD 510 k | Comprar |
180,225
+76,421
| +74% | +USD 339 k | ﹤0.01% | 4431 |
|
|
2015
Q4 | USD 1.07 M | Comprar |
103,804
+12,646
| +14% | +USD 126 k | ﹤0.01% | 3999 |
|
|
2015
Q3 | USD 1.04 M | Vender |
91,158
-7,934
| -8% | -USD 106 k | ﹤0.01% | 4074 |
|
|
2015
Q2 | USD 1.48 M | Comprar |
99,092
+327
| +0.3% | +USD 3.72 k | ﹤0.01% | 3895 |
|
|
2015
Q1 | USD 892 k | Comprar |
98,765
+37,571
| +61% | +USD 389 k | ﹤0.01% | 4217 |
|
|
2014
Q4 | USD 745 k | Vender |
61,194
-227,022
| -79% | -USD 2.51 M | ﹤0.01% | 4368 |
|
|
2014
Q3 | USD 2.82 M | Vender |
288,216
-202,818
| -41% | -USD 2.49 M | ﹤0.01% | 3161 |
|
|
2014
Q2 | USD 6.26 M | Vender |
491,034
-34,272
| -7% | -USD 333 k | ﹤0.01% | 2465 |
|
|
2014
Q1 | USD 5.56 M | Vender |
525,306
-7,706
| -1% | -USD 82.2 k | ﹤0.01% | 2493 |
|
|
2013
Q4 | USD 4.05 M | Comprar |
533,012
+458,179
| +612% | +USD 2.9 M | ﹤0.01% | 2768 |
|
|
2013
Q3 | USD 544 k | Vender |
74,833
-104,494
| -58% | -USD 530 k | ﹤0.01% | 4273 |
|
|
2013
Q2 | USD 278 k | Comprar |
+179,327
| Nuevas | +USD 309 k | ﹤0.01% | 4646 |
|
Otros fondos que tienen BCRX en su cartera
Posición de Morgan Stanley en BCRX: resumen de T2 2026
Morgan Stanley redujo su participación en BioCryst Pharmaceuticals (BCRX) en 1.2% durante T2 2026, al vender acciones por un valor estimado de USD 211 k, y conservó 1,999,684 acciones valuadas en USD 20 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #3100.
Morgan Stanley reportó por primera vez una posición en BCRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 47.8 M en T2 2025. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, Morgan Stanley tenía 1,999,684 acciones de BioCryst Pharmaceuticals con un valor de USD 20 M.
- Morgan Stanley vendió 23,304 acciones de BioCryst Pharmaceuticals en T2 2026, por un valor estimado de USD 211 k.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 3100.
- Morgan Stanley reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de Morgan Stanley en BioCryst Pharmaceuticals alcanzó su máximo de USD 47.8 M en T2 2025.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.